Display options
Cite
Wons J, Wirth MA, Graf N, et al. Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept. J Ophthalmol. 2017;2017:7432739doi: 10.1155/2017/7432739.
Wons, J., Wirth, M. A., Graf, N., Becker, M. D., & Michels, S. (2017). Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept. Journal of ophthalmology, 20177432739. https://doi.org/10.1155/2017/7432739
Wons, Juliana, et al. "Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept." Journal of ophthalmology vol. 2017 (2017): 7432739. doi: https://doi.org/10.1155/2017/7432739
Wons J, Wirth MA, Graf N, Becker MD, Michels S. Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept. J Ophthalmol. 2017;2017:7432739. doi: 10.1155/2017/7432739. Epub 2017 Feb 20. PMID: 28316836; PMCID: PMC5338067.
Copy Download .nbib Format: NLM
Share it on

J Ophthalmol. 2017;2017:7432739. doi: 10.1155/2017/7432739. Epub 2017 Feb 20.

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept.

Journal of ophthalmology

Juliana Wons, Magdalena A Wirth, Nicole Graf, Matthias D Becker, Stephan Michels

Affiliations

  1. City Hospital Triemli, Zurich, Switzerland.
  2. Graf Biostatistics, Winterthur, Switzerland.
  3. City Hospital Triemli, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.

PMID: 28316836 PMCID: PMC5338067 DOI: 10.1155/2017/7432739

[No abstract available.]

Conflict of interest statement

The authors Magdalena A. Wirth and Juliana Wons declare the freedom of any potential conflicting interests, certifying that they have no affiliations with or involvement in any organization or entity

References

  1. Am J Ophthalmol. 2015 May;159(5):915-24.e2 - PubMed
  2. Am J Ophthalmol. 2007 Jun;143(6):995-1002 - PubMed
  3. Ophthalmology. 2014 Jan;121(1):150-61 - PubMed
  4. Br J Ophthalmol. 2015 Oct;99(10):1341-4 - PubMed
  5. Br J Ophthalmol. 2016 Feb 17;:null - PubMed
  6. Lancet Glob Health. 2014 Feb;2(2):e106-16 - PubMed
  7. Expert Opin Pharmacother. 2013 Jun;14(8):1017-28 - PubMed
  8. Ophthalmology. 2015 Apr;122(4):809-16 - PubMed
  9. Invest Ophthalmol Vis Sci. 2015 Jan 13;56(2):875-82 - PubMed
  10. Br J Ophthalmol. 2014 Jun;98(6):813-25 - PubMed
  11. Clin Ophthalmol. 2015 Nov 20;9:2159-74 - PubMed
  12. Ophthalmology. 2011 Apr;118(4):679-86 - PubMed
  13. Ophthalmic Surg Lasers Imaging. 2011 Jul;42 Suppl:S56-66 - PubMed
  14. Am J Ophthalmol. 2007 Mar;143(3):463-72 - PubMed
  15. Ophthalmology. 2012 Jul;119(7):1388-98 - PubMed

Publication Types